GV has returned for a $95.4m series C round that also included Eli Lilly through the conversion of a $10m note secured as part of a collaboration agreement last year.
UK-based exosome drug developer Evox Therapeutics raised £69.2m ($95.4m) in a series C round yesterday featuring GV, a corporate venturing arm of internet technology group Alphabet, and pharmaceutical firm Eli Lilly. Redmile Group led the round and was joined by OrbiMed, Invus, University of Oxford and its patient capital fund Oxford Sciences Innovation (OSI), Panacea…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.